跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2004-003953-16-IT
EUCTR2004-003953-16-IT进行中（未招募）不适用

A one-year,open-label,single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload.

OVARTIS FARMA0 个研究点目标入组 1,541 人开始时间: 2005年6月22日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
进行中（未招募）
发起方
OVARTIS FARMA
入组人数
1,541
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •see protocol
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •see protocol

研究者

发起方
OVARTIS FARMA

相似试验

进行中（未招募）
不适用
A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload
EUCTR2004-003953-16-DEovartis Pharma Services AG1,541
进行中（未招募）
不适用
A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload.
EUCTR2004-003953-16-ATovartis Pharma Services AG1,541
进行中（未招募）
不适用
A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantation in whom iron overload is present
EUCTR2006-003970-89-DEovartis Pharma GmbH
进行中（未招募）
不适用
A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overloadEstudio multicéntrico, abierto, de un solo grupo y de un año de duración, para evaluar la eficacia y seguridad de ICL670 (20 mg/kg/día) administrado vía oral en pacientes diagnosticados de sobrecarga férrica asociada a transfusiones
EUCTR2004-003953-16-ESovartis Farmacéutica, S.A.1,541
进行中（未招募）
1 期
A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload.
EUCTR2004-003953-16-BEovartis Pharma Services AG1,541